Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 1167

Next Previous
Drug Profile

HRS 1167

Alternative Names: HRS-1167; M-9466

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer EMD Serono Research & Development Institute; Jiangsu Hengrui Medicine Co.; Merck KGaA
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
  • Phase I Colorectal cancer; Solid tumours

Most Recent Events

  • 02 Jun 2026 Preliminary efficacy and adverse events data from phase I DDRiver 501 trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 29 May 2026 Efficacy, and adverse events data from a phase Ib/II trial in Prostate cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (AACR-2026)
  • 08 Oct 2025 Phase-I development is ongoing in Solid-tumours (Late-stage disease) in China (PO, Tablet) (NCT05473624)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top